Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Fda    crawled time : 13:03    save search

Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
Published: 2021-03-01 (Crawled : 13:03) - globenewswire.com
AVDL | $18.075 4.48% 4.29% 990K twitter stocktwits trandingview |
Health Technology
| | O: 0.75% H: 4.57% C: 2.22%

new drug treatment fda drug ft218 fda acceptance narcolepsy
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
Published: 2021-02-28 (Crawled : 13:03) - globenewswire.com
BBIO | $25.43 1.44% 1.42% 1.1M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

fda risk fda approval therapy approval
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA
Published: 2021-02-23 (Crawled : 13:03) - globenewswire.com
SCPH | $4.6 0.66% 0.65% 85K twitter stocktwits trandingview |
Health Technology
| | O: -0.14% H: 2.56% C: 0.43%

fda results
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
Published: 2021-02-22 (Crawled : 13:03) - globenewswire.com
ITCI 4 d | $73.96 -0.78% -0.78% 830K twitter stocktwits trandingview |
Health Technology
| | O: 1.19% H: 0.06% C: -2.53%

treatment fda fda approval depression approval therapy
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
Published: 2021-02-22 (Crawled : 13:03) - globenewswire.com
SUPN | $29.98 0.91% 0.9% 200K twitter stocktwits trandingview |
Health Technology
| | O: 0.03% H: 0.91% C: -1.22%

fda pdufa
Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA
Published: 2021-02-01 (Crawled : 13:03) - globenewswire.com
ZSAN | $0.5576 7.23% -5.85% twitter stocktwits trandingview |
Health Technology
| | O: 21.77% H: 0.0% C: -12.5%

fda submission resubmission pharma
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Knoxville, TN
Published: 2021-02-01 (Crawled : 13:03) - globenewswire.com
ADMA 4 | $6.535 5.4% 5.13% 2.7M twitter stocktwits trandingview |
Health Technology
| | O: 5.86% H: 5.53% C: 4.26%

fda approval fda approval
VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update
Published: 2021-02-01 (Crawled : 13:03) - globenewswire.com
VYNE | $2.345 -0.21% -0.21% 30K twitter stocktwits trandingview |
Health Technology
| | O: 6.06% H: 11.9% C: 9.52%

fda approval fda approval therapeutics
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
Published: 2021-01-25 (Crawled : 13:03) - globenewswire.com
ALBO | $44.15 -0.23% 0.39% 1.2M twitter stocktwits trandingview |
Health Technology
| | O: 4.34% H: 3.88% C: -0.55%

fda drug fda acceptance new drug application
Inari Medical’s FlowTriever System Receives FDA 510(k) Clearance for Treatment of Right Atrial Clot in Transit
Published: 2021-01-08 (Crawled : 13:03) - globenewswire.com
NARI S | $37.13 -2.11% -2.15% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 1.38% H: 2.66% C: 2.31%

fda trial treatment clearance
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
Published: 2020-12-28 (Crawled : 13:03) - globenewswire.com
CNSP | News | $0.201 0.95% 0.95% 120K twitter stocktwits trandingview |
Health Technology
| | O: 1.8% H: 4.86% C: 2.1%

fda approval fda approval broadcast application
Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
Published: 2020-12-21 (Crawled : 13:03) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 7.89% H: 0.98% C: -11.24%

fda drug new drug application
Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain
Published: 2020-12-11 (Crawled : 13:03) - globenewswire.com
LXRX | $1.62 -5.26% -5.56% 3.5M twitter stocktwits trandingview |
Health Technology
| | O: 22.59% H: 0.74% C: -23.34%

fda diabetic diabetes fast track fast track designation designation
Gainers vs Losers
78% 22%

Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M twitter stocktwits trandingview |

AGBA | $2.94 135.2% 57.48% 66M twitter stocktwits trandingview |
Finance

EDBL | News | $6.46 71.81% 41.8% 2M twitter stocktwits trandingview |

MTC | $2.25 44.23% 30.67% 6M twitter stocktwits trandingview |
Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M twitter stocktwits trandingview |
Finance

SHIM | $3.05 35.56% 26.23% 1.1M twitter stocktwits trandingview |

HKIT | $1.345 31.86% 24.16% 390K twitter stocktwits trandingview |
Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M twitter stocktwits trandingview |
Wholesale Trade

OST | $0.512 28.0% 21.88% 290K twitter stocktwits trandingview |

POET | $1.59 27.2% 21.38% 4.2M twitter stocktwits trandingview |
Manufacturing


Your saved searches
Save your searches and get alerts when important news are released.